TO DETERMINE THE USE OF AN LNG-IUS FOR CONSERVATIVE MANAGEMENT IN WOMEN WITH SYMPTOMATIC MILD TO MODERATE ENDOMETRIOSIS
article
OA: bronze
CC0
Abstract
BACKGROUND: Medical treatment of endometriosis, a condition which significantly affects the quality of life in only 10–15% of women in the reproductive years, rest have no improvement. Although oral progestogens are effective and cheap, their efficacy is significantly influenced by poor compliance and systemic side effects. A progestogen (levonorgestrel) administered via an intrauterine system (Lng‐IUS) has been demonstrated to improve symptoms of endometriosis; however, its effect on the staging of the disease has not been evaluated. OBJECTIVE: The aims of this study were therefore to investigate the effectiveness of Lng‐IUS in the symptomatic relief of minimal to moderate endometriosis and in the staging of the disease. METHODS: This was a prospective non‐comparative observational study in which 33 women with clinically suspected and also confirmed by laparoscopically symptomatic minimal to moderate endometriosis had Lng‐IUS inserted for 6 months. The symptom profile and stage of the disease before, during and after 6 months of treatment and patients’ satisfaction with treatment and willingness to retain the device at the end of the study period were used to assess response to treatment. RESULTS: Out of the 33 women recruited, 29 (87%) completed the study; four discontinued. Rest 29 patients had significant improvements in severity and frequency of pain and menstrual symptoms as well as staging were achieved, and elected to continue with the device after 6 months of therapy. CONCLUSION: The levonorgestrel intrauterine system is an effective hormonal option for treating symptomatic endometriosis (minimal to moderate). It has the potential for providing long‐term therapy in a substantial number of sufferers, although this would require further study and verification.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (24)
- A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study via openalex
- Current Concepts in the Pathogenesis of Endometriosis via openalex
- Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium via openalex
- Epidemiology of endometriosis among parous women via openalex
- Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. via openalex
- Levonorgestrel‐releasing intrauterine device in the treatment of menorrhagia via openalex
- Medical Treatment of Endometriosis via openalex
- Menstrual characteristics in women with and without endometriosis via openalex
- The role of definitive surgery and hormone replacement therapy in the treatment of endometriosis via openalex
- Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis via openalex
- Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. via openalex
- W2046921112 via openalex
- W1994486622 via openalex
- W2057022929 via openalex
- W1986666488 via openalex
- W2070900245 via openalex
- W1984063724 via openalex
- W2101734337 via openalex
- W2133648796 via openalex
- W106328369 via openalex
- W2042374015 via openalex
- W2477008945 via openalex
- W2031785143 via openalex
- W2009645249 via openalex
Source provenance
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0
· commercial use OK